These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 12370823

  • 1. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
    Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J.
    Oncogene; 2002 Oct 10; 21(46):7011-26. PubMed ID: 12370823
    [Abstract] [Full Text] [Related]

  • 2. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
    Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J.
    Cancer Res; 2006 Nov 01; 66(21):10315-24. PubMed ID: 17079451
    [Abstract] [Full Text] [Related]

  • 3. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.
    Mol Cancer Res; 2002 Nov 01; 1(1):2-11. PubMed ID: 12496364
    [Abstract] [Full Text] [Related]

  • 4. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
    Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J.
    FASEB J; 2005 Nov 01; 19(13):1884-6. PubMed ID: 16166198
    [Abstract] [Full Text] [Related]

  • 5. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ.
    Cancer Res; 1999 Oct 15; 59(20):5209-18. PubMed ID: 10537299
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of retinal neovascularization by soluble EphA2 receptor.
    Chen J, Hicks D, Brantley-Sieders D, Cheng N, McCollum GW, Qi-Werdich X, Penn J.
    Exp Eye Res; 2006 Apr 15; 82(4):664-73. PubMed ID: 16359662
    [Abstract] [Full Text] [Related]

  • 7. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
    Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J.
    J Cell Sci; 2004 Apr 15; 117(Pt 10):2037-49. PubMed ID: 15054110
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
    Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP.
    Clin Cancer Res; 2002 Apr 15; 8(4):1258-70. PubMed ID: 11948141
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
    Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG.
    Cell Growth Differ; 1998 Jan 15; 9(1):49-58. PubMed ID: 9438388
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1558-70. PubMed ID: 17077358
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
    Oncogene; 2005 Jan 27; 24(5):790-800. PubMed ID: 15592523
    [Abstract] [Full Text] [Related]

  • 14. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
    Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM, Noël A.
    Cancer Res; 2001 Apr 15; 61(8):3450-7. PubMed ID: 11309307
    [Abstract] [Full Text] [Related]

  • 15. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
    Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM.
    Cancer Res; 1996 Apr 01; 56(7):1615-20. PubMed ID: 8603410
    [Abstract] [Full Text] [Related]

  • 16. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, Imazu H, Fukui H.
    Int J Oncol; 2002 Jun 01; 20(6):1227-31. PubMed ID: 12012003
    [Abstract] [Full Text] [Related]

  • 17. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
    Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J.
    Oncogene; 2005 Nov 24; 24(53):7859-68. PubMed ID: 16103880
    [Abstract] [Full Text] [Related]

  • 18. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.
    Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF.
    Cancer Res; 2002 Jun 01; 62(11):3077-83. PubMed ID: 12036917
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.
    Cancer Res; 2009 Oct 15; 69(20):8009-16. PubMed ID: 19808973
    [Abstract] [Full Text] [Related]

  • 20. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM.
    Nat Med; 2003 Aug 15; 9(8):1026-32. PubMed ID: 12872165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.